health
Phase 2b Trial Finds Potential Benefit for Mebufotenin Spray in Resistant Depression
A single administration of an experimental, fast-acting psychedelic nasal spray containing synthetic mebufotenin benzoate was associated with improved depression scores over 29 days in a phase 2b trial of adults with treatment-resistant depression, according to randomized…
